Document:

Exhibit 10.76

 

August 13, 2015

 

By Hand

 

Martin P. Rosendale

1915 Long Corner Road

Mount Airy, MD 21771

Dear Marty:

 

As we have discussed, your last day of work
with Nuo Therapeutics, Inc. f/k/a Cytomedix, Inc. (“Nuo Therapeutics” or the “Company”) will be today,
August 13, 2015. This letter agreement (“Agreement”) sets forth the terms of your separation from the Company. As this
is a legal document, you are advised to consult with an attorney before signing it.

 

1.            Separation Date. The effective
date of your separation from Nuo Therapeutics will be August 15, 2015 (“Separation Date”). Your last day of work will
be August 13, 2015. You will be paid your regular base salary through the Separation Date. You will also be paid your 244 accrued
but unused vacation hours in the amount of $45,164.40. You must submit your final expense report, if any, no later than August
31, 2015, and you will be reimbursed in accordance with Company policy. All benefits incident to your employment cease as of the
Separation Date, subject to your right to elect COBRA.

 

2.            Consideration. In exchange
for your agreeing to and complying with the terms of this Agreement (including the general release it contains), Nuo Therapeutics
will pay or provide the following:

 

(a)            Your regular base salary from the
Separation Date through February 15, 2016 (“Salary Continuation Date”), less applicable taxes, on the Company’s
regular paydays, provided however, that your initial salary continuation payments may be deferred by up to ten (10) business days
after the Effective Date of this Agreement (as defined in paragraph 14(g) below);

 

(b)            A lump sum of $192,500, less applicable
taxes, after January 1, 2016 but no later than February 28, 2016 provided that the Company secures funding or funding commitments
(included tranched or milestone based funding) that covers its 2016 operating plan as established by the Board of Directors, and
provided further that if Company’s funding (as of February 28, 2016) is not sufficient to cover the 2016 operating plan,
the lump sum payment will be paid when such funding is sufficient to cover the 2016 operating plan, but no later than December
31, 2016;

 

(c)            Assuming that you sign below and
that you elect COBRA continuation for your medical, dental, and/or vision coverage, you will receive such coverage as you elect
to continue on the same terms and conditions as active employees through your Salary Continuation Date. Until the earlier of (i) twelve
(12) months after your Salary Continuation Date, or (ii) you become eligible for comparable benefits from another employer,
the Company will reimburse you for the cost of your COBRA coverage. Thereafter, you will have the right to continue such coverages
at your expense through COBRA.

 

    	 	 	 

    	August 13, 2015
 Page 2

    

 

3.            Indemnification and Potential Consulting.
Consistent with the Company’s bylaws, the Company will continue to indemnify you with respect to any actions taken or omissions
made by you serving as an officer or director of the Company. In view of the Company’s potential need for your services after
the Separation Date, you agree to make yourself available for consulting with the Company upon such reasonable terms upon which
the Company and you may agree. The Company’s indemnification obligation will continue with respect to any actions taken or
omissions made by you serving as a consultant to the Company. The Company and you hereby ratify and confirm that they entered into
an Indemnification Agreement dated November 11, 2014 and that in the event that there is any conflict between the indemnification
provisions in this paragraph and said Indemnification Agreement, the Indemnification Agreement shall govern.

 

4.            Acknowledgement of Equity.
The Company and you recognize and acknowledge that you own 229,149 shares of the Company’s common stock and 1,315,000 vested
options pursuant to the terms of the individual grant agreements pursuant to which such options were granted and the Company’s
stock option plan.

 

5.            Acknowledgement of Receipt of all
Remuneration. Except as set forth in paragraphs 2, 3, and 4 above, you agree and acknowledge that you are not entitled to receive
any payments, commissions, bonuses, severance, benefits, equity, options, or other remuneration of any kind.

 

6.            General Releases. (a) In exchange
for the salary and benefits continuation provided pursuant to this Agreement, you, on behalf of yourself and your heirs, executors,
administrators and assigns, hereby irrevocably, fully, and unconditionally release and forever discharge jointly and severally
Nuo Therapeutics and any and all of its current and former direct and indirect affiliates, divisions, partners, its employment
benefit plans and trustees, fiduciaries and administrators of these plans and any of the foregoing parties’ present or past
employees, officers, directors, stockholders, members, joint ventures, agents and contractors and each of their predecessors, successors
and assigns (collectively “Released Parties”), from all actions, claims, obligations, liabilities, demands and causes
of action, known or unknown, fixed or contingent, in law or equity, which you ever had, now have or hereafter can, shall or may
have for, upon or by reason of any matter, cause or thing occurring up to and including the date you sign this Agreement, including,
but not limited to any claim under the Age Discrimination in Employment Act (“ADEA”), Americans with Disabilities Act
(“ADA”), the Employee Retirement Income Security Act of 1974 (“ERISA”), the Fair Credit Reporting Act (“FCRA”),
the Family and Medical Leave Act (“FMLA”), the Occupational Safety and Health Act of 1970 (“OSHA”), the
Rehabilitation Act of 1973, the Sarbanes Oxley Act of 2002, Title VII of the Civil Rights Act of 1964, the Workers Adjustment and
Restraining Notification Act (“WARN”), the Maryland Equal Pay Law, the Maryland Fair Employment Practices Act, the
Maryland Parental Leave Law, and any and all federal, state and local laws, rules, regulations or common law relating to discrimination,
retaliation, whistleblowing, defamation, misrepresentation, fraud, tortious interference, wrongful discharge, breach of an express
or implied contract, breach of a covenant of good faith and fair dealing, negligent or intentional infliction of emotional distress;
and any and all claims you may have against any of the Released Parties, including, but not limited to, any claims arising under
your Employment Agreement with Nuo Therapeutics dated May 14, 2014 (the “Employment Agreement”).

 

    	 	 	 

    	August 13, 2015
 Page 3

    

 

(b) In exchange for your obligations
under this Agreement, Nuo Therapeutics and Nuo’s past, present and future parents, subsidiaries and affiliates or any
party claiming by or through Nuo hereby irrevocably, fully, and unconditionally releases and forever discharges jointly and
severally you, your heirs, executors, administrators and assigns from all actions, claims, obligations, liabilities, demands
and causes of action, known or unknown, fixed or contingent, in law or equity, which the Company ever had, now has or
hereafter can, shall or may have for, upon or by reason of any matter, cause or thing occurring up to and including the date
the Company signs this Agreement, provided however, that the Company does not release you from any claims related to fraud or
criminal conduct.

 

7.            Cooperation. You agree that
you will reasonably cooperate with Nuo Therapeutics and its officers and employees to provide transition support in connection
with any matter on which your cooperation may reasonably be requested or of which you had knowledge. You agree that, in the event
that you are subpoenaed by any person or entity (including but not limited to, any government agency) to give testimony (in a deposition,
court proceeding or otherwise) which in any way relates to your employment with Nuo Therapeutics, you will give prompt notice of
such request (unless prohibited by law) to the Chief Financial Officer of Nuo Therapeutics and will, to the extent practicable,
make no disclosure until Nuo Therapeutics has had a reasonable opportunity to contest the right of the requesting party or entity
to such disclosure. You further agree that, in the event that you are contacted by any person or entity regarding information concerning
Nuo Therapeutics or one of its affiliates, you will give prompt notice of such request (unless prohibited by law) to the Chief
Financial Officer of Nuo Therapeutics, and will make no disclosure until Nuo Therapeutics has had a reasonable opportunity to respond
to your notification.

 

8.            Restrictive Covenants. You
agree that, beginning on the Separation Date, and continuing for a period of six (6) months thereafter, you will not directly or
indirectly: (a) organize, own, manage, operate, join, control, finance, or participate in any business, enterprise or entity
engaged anywhere in the world in competition with Nuo Therapeutics with respect to any business or activity that is substantially
related to the development, marketing, distribution, sale, or concerned with autologous point of care platelet separation technology;
(b) hire any person employed by or engaged to provide services relating to the business of Nuo Therapeutics, or employed or
so engaged by Nuo Therapeutics within one (1) year prior to the Separation Date, or solicit, induce or attempt to induce any such
person to leave the employment of Nuo Therapeutics; or (c) solicit or attempt to solicit any business from any of Nuo Therapeutics'
customers, customer prospects, or vendors with whom you had contact with during your employment. Additionally, you acknowledge
and agree that any writing, invention, design, system, process, development or discovery, conceived, developed, created or made
by you, alone or with others, within one (1) year following the Separation Date is the sole and exclusive property of Nuo Therapeutics
if it (i) relates to Nuo Therapeutics’ autologous point of care platelet separation technology and/or (ii) is based
upon or related to information or processes learned or performed during your employment, whether or not it can or may be patented,
registered, or copyrighted.

 

    	 	 	 

    	August 13, 2015
 Page 4

    

 

9.            Return of Property. You hereby
confirm and acknowledges that you have returned to the Company any and all equipment, security badges, keys, credit cards, passwords,
files, confidential information, or other property of the Company and its subsidiaries over which you ever had possession, custody,
or control in connection with your employment. You also affirm that you are in possession of all of your property that you had
at the Company’s premises and that the Company is not in possession of any of your property.

 

10.            Non-Disparagement. Except
as may be required by law, you agree not to engage in any form of conduct, or make any statements or representations, that disparage
or otherwise impair the reputation, goodwill, or commercial interests of the Company, its management, officers and directors, and/or
other direct or indirect affiliates of the Company and their respective management, officers and directors. Similarly, the Company
agrees that it shall direct its officers and directors not to in any form of conduct, or make any statements or representations
to any third parties, that disparage or otherwise impair your reputation, goodwill, or commercial interests.

 

11.            Choice of Law and Consent to Jurisdiction.
This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware without regard to its conflict
of laws provisions or principles. You irrevocably consent to the exclusive personal jurisdiction of the appropriate state or federal
court for Montgomery County, Maryland and waive any objection you may have based upon lack of personal jurisdiction, improper venue,
or forum non conveniens.

 

12.            Severability. Should any provision
of this Agreement be declared illegal or unenforceable by any court of competent jurisdiction and cannot be modified to be enforceable,
excluding the general release language, such provision shall immediately become null and void, leaving the remainder of this Agreement
in full force and effect.

 

13.            Entire Agreement. This Agreement
sets forth the entire agreement between the parties hereto, and fully supersedes any prior agreements or understandings regarding
your employment with the Company and may not be modified or amended without the prior written consent of both parties hereto. You
acknowledge that you have not relied on any representations, promises, or agreements of any kind made to you, except for those
set forth in this Agreement.

 

14.            Meaning of Signing This Agreement.
By signing this Agreement, you expressly acknowledge and agree that:

 

(a)            You have carefully read this Agreement
and fully understand what it means;

 

    	 	 	 

    	August 13, 2015
 Page 5

    

 

(b)            You have been advised in writing
to discuss this Agreement with an attorney before signing it;

 

(c)            You have been given at least forty-five
(45) calendar days to consider this Agreement;

 

(d)            You have been given a list of the
job titles and ages of all individuals eligible for this severance program and the job titles and ages of all individuals in the
Company who are not eligible for this program (see Appendix A);

 

(e)            You have agreed to this Agreement
knowingly and voluntarily; you were not subject to any undue influence or duress; and you are competent to execute this document;

 

(f)            You may revoke your acceptance of
this Agreement within seven (7) days after you sign it by sending written Notice of Revocation by e-mail to Susan Ways (SWays@nuot.com);
and

 

(g)            On the eighth (8th) day after you
sign this Agreement (the “Effective Date”), this Agreement becomes effective and enforceable if it has not been revoked.

 

15.            Return of Signed Agreement.
You may accept this Agreement by signing the Agreement and returning it by regular mail to Susan Ways, Nuo Therapeutics, Inc.,
207A Perry Parkway, Suite 1, Gaithersburg, MD 20877 or by e-mail to Susan Ways (SWays@nuot.com), within forty-five (45) days after
you receive it. In the event you do not accept this Agreement as set forth above, this Agreement, including but not limited to
the obligation of the Company to provide the payment and other benefits described in Paragraphs 2 and 3 above, shall be deemed
automatically null and void.

 

	 	 	 	Nuo Therapeutics,
Inc.	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	/s/ David Jorden	 
	 	 	 	 	 
	 	 	 	David Jorden	 
	 	 	 	Interim Chief Financial Officer	 
	 	 	 	 	 
	Accepted and Agreed:	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	/s/ Martin P. Rosendale	 	Dated:	13 August	, 2015
	Martin P. RosendaleExhibit 10.77

 

AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT

 

This AMENDMENT NO.
2 (“Amendment No. 2”) to the Employment Agreement by and between Dean Tozer (the “Employee”)
and Nuo Therapeutics, Inc. (formerly, Cytomedix, Inc.) (the “Company”, and together with Executive, the “Parties”),
dated as of May 30, 2014 (the “Original Employment Agreement”), is entered into as of August 13, 2015, by and
between Employee and the Company. Capitalized terms used but not defined in this Amendment No. 2 shall have the same meaning ascribed
to them in the Original Employment Agreement.

 

RECITALS

 

WHEREAS, the
Parties entered into the Original Employment Agreement;

 

WHEREAS, the
Parties entered into an amendment to the Original Employment Agreement dated as of July 15, 2014 (“Amendment No. 1”,
and together with the Original Employment Agreement, the “Employment Agreement”); and

 

WHEREAS, in
connection with the appointment of Employee as the President and Chief Executive Officer of the Company, the Parties desire to
amend the Employment Agreement as set forth herein.

 

NOW, THEREFORE,
in consideration of the mutual covenants contained herein, and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties hereto agree as follows:

 

1.     All references
in the Employment Agreement to “Cytomedix, Inc.” are hereby replaced with “Nuo Therapeutics, Inc.”

 

2.     The term “Effective
Date” in the Employment Agreement shall hereby be amended to mean August 15, 2015.

 

3.     The second WHEREAS
clause in the Employment Agreement is hereby amended and restated in its entirety as follows:

 

“WHEREAS, the Company
and the Employee desire the Employee to serve as President and Chief Executive Officer; and”

 

4.     Term of Employment;
Office and Duties.

 

		a.	Section 1(a) of the Employment Agreement is hereby amended and restated in its entirety as follows:

 

“(a)     Commencing as of
the Effective Date and continuing through December 31, 2016 (the “Term”), and subject to the terms and conditions
herein, the Company agrees to employ Employee as President and Chief Executive Officer (“CEO”), based in and around
the Nashville, TN area, with the duties and responsibilities prescribed for such office in the bylaws of the Company and such additional
duties and responsibilities consistent with such positions, as may, from time to time, be assigned to the Employee by the Board
of Directors of the Company (the “Board”). Employee agrees to devote his full energy and efforts and to work
full time as President and CEO of the Company, to work at the location or locations necessary to fulfill such duties, and to perform
such duties and discharge such responsibilities in accordance with the terms of this Agreement in a diligent and professional manner
and in the best interest of the Company.”

 

		b.	The last sentence of Section 1(b) of the Employment Agreement is hereby deleted and replaced with
the following:

 

“The Employee must obtain
the Board’s consent prior to accepting any new board of director positions, board committee memberships, or consulting work
subsequent to the Effective Date, which consent shall not be unreasonably withheld by the Board.”

 

    	 	 	 

     

    

 

5.     Compensation
and Benefits.

 

		a.	Base Salary. The first sentence of Section 2(a) of the Employment Agreement is hereby deleted
and replaced with the following:

 

“The Company shall pay
the Employee a fixed salary (the “Base Salary”) in the gross amount of Three Hundred Sixty-Five Thousand Dollars
($365,000) per year.”

 

		b.	Annual Bonus. Section 2(b) of the Employment Agreement is hereby amended and restated in
its entirety as follows:

 

“(b)     Annual Bonus.
In lieu of an annual bonus for 2015 and 2016, for the Fiscal Year ending December 31, 2016 only, Employee shall be entitled to
receive a one-time, special cash bonus, in the amount of up to 80% of Employee’s Base Salary (the “Annual Bonus”).
The “Fiscal Year” is the period beginning on each January 1 and ending on the following December 31. In order
for the Employee to receive the Annual Bonus, the Evaluation Criteria as established by the Board, on the recommendation of the
Compensation Committee of the Board (the “Compensation Committee”), in consultation with the Employee, must
be satisfied. As used herein, the term “Evaluation Criteria” refers to such corporate and financial performance
goals and objectives for such Fiscal Year as determined by the Compensation Committee in consultation with the Employee. The Evaluation
Criteria shall be determined by the later of (i) September 30, 2015, and (ii) ten (10) days after the modification of
the Deerfield Facility Agreement is finalized.”

 

 6.     Fringe Benefits, Option Grants and Miscellaneous Employment Matters.

 

		a.	The following provision is hereby inserted in the Employment Agreement as Section 2(d)(iii):

 

“(iii) Notwithstanding anything to the contrary
in this Agreement, in the event that the Company issues additional equity, convertible debt or equity appreciation rights to Deerfield
Management Company, L.P. or its affiliates (collectively “Deerfield”) in connection with the Company’s
modification of that certain Facility Agreement, dated as of March 31, 2014, as amended, between the Company and Deerfield (the
“Deerfield Facility Agreement”, and such issuance, the “Deerfield Dilutive Issuance”), then
the Company shall, as soon as practicable and as part of a one-time adjustment, issue additional Employment Options to Employee
in an amount such that the Employment Option Percentage as of the Effective Date shall equal the Employment Option Percentage as
of the date of the Deerfield Dilutive Issuance, as adjusted for the Deerfield Dilutive Issuance only. As used herein, the term
“Employment Option Percentage” means the percentage of the Company’s fully diluted issued and outstanding
capital stock represented by the Employment Options held by Employee as of the Effective Date. Furthermore, in the event that the
Deerfield Dilutive Issuance consists of equity with preferences senior to the Company’s common stock, the Company shall,
subject to receipt of any necessary consents from Deerfield and any other investors related to the Deerfield Dilutive Issuance,
issue a mix of additional Employment Options to Employee so that Employees ownership of common and preferred stock in the Company
mirrors the mix of common and preferred stock of the fully diluted capitalization table of the Company. For illustrative purposes
only, if after the Deerfield Dilutive Issuance the fully diluted capitalization table of the Company consists of 30% preferred
stock and 70% common stock, then the Company as part of the one-time adjustment shall issue a mix of common and preferred stock
Employment Options to Employee so that after such issuance Employee’s fully diluted ownership of the Company would consist
of 30% preferred stock and 70% common stock.”

 

		b.	The following provision is hereby inserted in the Employment Agreement as Section 2(d)(iv):

 

“(iv) Prior to
September 30, 2015, the Board and Employee shall finalize good faith discussions regarding additional grants of Employment Options
to Employee.”

 

    	 	2	 

     

    

 

7.     Termination
of Employment.

 

		a.	Section 4(b)(A) of the Employment Agreement is hereby amended by deleting the words “six
(6) months” and replacing them with “twelve (12) months, or solely in the event Employee remains as the CEO following
December 31, 2016 and the Company achieves certain performance criteria to be established by the Board in consultation with the
Employee by the later of (i) September 30, 2015, and (ii) ten (10) days after the modification of the Deerfield Facility
Agreement is finalized, eighteen (18) months”.

 

		b.	Section 4(c)(iii) of the Employment Agreement is hereby amended by deleting the words “Executive
Vice President, Chief Commercial Officer” and replacing them with “President and Chief Executive Officer”.

 

		c.	Section 4(d) of the Employment Agreement is hereby amended by deleting the words “thirty
(30) days” and replacing them with “sixty (60) days”.

 

		d.	Section 4(g) shall be added to the Employment Agreement as follows: “Upon termination of
Employee’s employment for any reason, Employee agrees to resign from the Board and any and all other positions, boards, and
committees of the Company.”

 

8.     Restrictive
Covenants. Sections 6(a) and 6(b) of the Original Employment Agreement are hereby amended by deleting the reference to “six
(6) months” and replacing it with “twelve (12) months”. Section 6(b) is further amended by deleting the phrase
“prior written consent of the Company signed by the CEO” and replacing it with “prior consent of the Board”.

 

9.     Notices:
Section 15(a) of the Employment Agreement is hereby amended and restated as follows:

 

	“(a) To the Company:
	 
	Nuo Therapeutics, Inc.
	207A Perry Parkway, Suite 1
	Gaithersburg, MD 20877
	Attn: Chairman of the Compensation Committee
	 
	and to:
	 
	Jeffrey Baumel, Esq.
	Dentons US LLP
	
        1221 Avenue of the Americas

        New York, New York 10020”

 

10.     Counterparts.
This Amendment No. 2 may be executed in one or more facsimile, electronic or original counterparts, each of which shall be deemed
an original and both of which together shall constitute the same instrument

 

11.     Ratification.
All terms and provisions of the Employment Agreement not amended hereby, either expressly or by necessary implication, are hereby
ratified and confirmed, and shall remain in full force and effect. From and after the date of this Amendment No. 2, all references
to the term “Employment Agreement” in this Amendment No. 2 or the terms “Agreement”,
“hereto”, “hereof” and “hereunder” or words of like
import shall mean the Employment Agreement as amended by this Amendment No. 2.

 

12.     Governing
Law. This Amendment No.2, including the validity, interpretation, construction and performance of this Amendment No. 2, shall
be governed by and construed in accordance with the laws of the State of Delaware applicable to agreements made and to be performed
in such State, without regard to such State’s conflicts of law principles.

 

    	 	3	 

     

    

 

13.     Entire Agreement.
This Amendment No. 2 shall be binding upon and inure to the benefit of and be enforceable by the respective successors and assigns
of the parties hereto. The Employment Agreement, as amended by this Amendment No. 2, embodies the entire agreement and understanding
between the Parties and supersedes all prior agreements and understandings relating to the subject matter hereof.

 

 

IN WITNESS WHEREOF,
the Parties have executed this Amendment No. 2 as of the date first written above.

 

	 	 	COMPANY:
	 	 	 
	 	 	NUO THERAPEUTICS, INC.
	 	 	 
	 	By:	/s/ David Jorden
	 	 	David Jorden
	 	 	Acting Chief Financial Officer
	 	 	 
	 	 	 
	 	 	EMPLOYEE:
	 	 	 
	 	 	/s/ Dean Tozer
	 	 	Dean Tozer

 

    	 	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]